Hims & Hers Health Inc. (HIMS) — RQD Stock Rating Cockpit

HIMS scores 63 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine (15/20): Reflects an ROIC of 8.4% and an FCF yield of 2.81%. This is a moderate pillar. The FCF yield is modest relative to the stock's valuation multiples, so a prospective investor is paying a high multiple for each dollar of free cash flow.
• Whale 13F Flow (13/20): Captures institutional accumulation and options positioning. Source detail behind this score is not itemized in the source data beyond the pillar label.
• Insider Conviction (11/20): Reflects SEC Form 4 and Congressional PTR cluster flow. This is the weakest of the positive-leaning pillars and gives little evidence of strong insider conviction in either direction.
• Macro Regime Fit (10/20): Reflects a beta of 1.05 and sector sensitivity. Beta slightly above 1 implies the stock has tended to move roughly in line with, or modestly more than, the broader market. This pillar is the lowest score, indicating the stock's current macro sensitivity is a headwind relative to the other factors.
• Forensic Balance Sheet (14/20): Reflects an Altman Z-Score of 3.95, a Piotroski F-Score of 8 out of 9, and a Debt/Equity ratio of 1.25. These are relatively strong forensic readings and are the second-highest pillar.

Taken together, the score profile suggests a company with a reasonably sound balance sheet and operating improvement, offset by a premium valuation, weak macro-regime fit, and limited insider conviction signals. For a prospective investor, the upside case depends on continued earnings and cash-flow expansion justifying elevated multiples, while the valuation tradeoff is that current multiples (P/E TTM of 53.9 and EV/EBITDA of 37.7) leave limited margin for error. This is an educational reading of the data, not a recommendation.

Hims & Hers Health Inc. Is a NYSE-listed issuer classified under the Health Care sector and the Medical/Nursing Services industry,. Gross margin is 73.8% per the market data, indicating a high-margin revenue base relative to operating margin of 4.5%. Specific products, customer segments, and monetization mechanics are —

Revenue grew from $872.0M in FY 2023 to $2.35B in FY 2025, and operating income moved from a loss to $105.6M over the same span. Per the market data, operating margin is 4.5%, net margin is 5.5%, and ROIC is 8.4%. The Altman Z-Score is 3.95 and the Piotroski F-Score is 8 out of 9. Debt rose from $103.9M in FY 2024 to $726.2M in FY 2025 while the Debt/Equity ratio is 1.25 .

• 🐂 Primary Bull Case: Revenue expanded from $872.0M in FY 2023 to $2.35B in FY 2025 while operating income turned positive to $105.6M, with a Piotroski F-Score of 8 out of 9. With Fundamental Cash Engine at 15/20 (ROIC 8.4%, FCF yield 2.81%) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $13.74 – $48.34 52-week range.
• 🐻 Primary Bear Case: A P/E (TTM) of 53.9 and EV/EBITDA of 37.7 sit against an FCF yield of only 2.81%, and debt climbed to $726.2M in FY 2025 from $103.9M in FY 2024. Investors must weigh 53.9x trailing P/E and 37.7x EV/EBITDA against 4.5% operating margins and a 1.05 macro beta if sector demand softens.

Upstream dependencies, downstream customers, and sector correlations beyond the Health Care sector and Medical/Nursing Services industry classification are — Investors should note that second-order ripple analysis cannot be performed from this dataset.

• Key Question #1: What drove the jump in FY 2025 debt to $726.2M from $103.9M in FY 2024, and what was the use of proceeds?
• Key Question #2: Reported EPS is absent for all periods; what are the reported per-share earnings figures behind the EPS (TTM) of 0.55?
• Key Question #3: What is the company's product mix, and how much of revenue derives from the newly launched international service lines?